Actinium Pharmaceuticals

OverviewSuggest Edit

Actinium Pharmaceuticals is a biopharmaceutical company developing targeted payload immunotherapeutics for the treatment of advanced cancers. Its targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company’s lead radiopharmaceutical Iomab™-B will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. Actinium is preparing a single, pivotal, multicenter Phase 3 clinical study of Iomab™-B in refractory and relapsed Acute Myeloid Leukemia (AML) patients over the age of 55 with a primary endpoint of durable complete remission. The Company’s second program, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.

TypePublic
Founded2000
HQNew York, US
Websiteactiniumpharma.com

Latest Updates

Employees (est.) (Mar 2019)30(+20%)
Share Price (Jun 2019)$0.3

Key People/Management at Actinium Pharmaceuticals

Sandesh Seth

Sandesh Seth

Chief Executive Officer and Chairman of the Board
Mark Berger

Mark Berger

Chief Medical Officer
Dale L. Ludwig

Dale L. Ludwig

Chief Scientific Officer
Anil Kapur

Anil Kapur

Chief Commercial Officer
David Gould

David Gould

Senior Vice President, Corporate Development and Affairs
Vijay Reddy

Vijay Reddy

Vice President, Clinical Development
Show more

Actinium Pharmaceuticals Office Locations

Actinium Pharmaceuticals has an office in New York
New York, US (HQ)
275 Madison Ave
Show all (1)

Actinium Pharmaceuticals Financials and Metrics

Actinium Pharmaceuticals Revenue

USD

Net income (Q2, 2019)

(5.0m)

EBIT (Q2, 2019)

(5.1m)

Market capitalization (10-Jun-2019)

42.1m

Closing stock price (10-Jun-2019)

0.3

Cash (30-Jun-2019)

19.5m

EV

22.7m
Actinium Pharmaceuticals's current market capitalization is $42.1 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

General and administrative expense

3.9m10.2m11.5m9.3m9.2m6.7m

R&D expense

12.3m

Operating expense total

6.6m22.4m24.8m26.8m26.9m23.8m

EBIT

(6.6m)(22.5m)(24.8m)(26.8m)(26.9m)(23.8m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

General and administrative expense

830.7k1.7m2.4m3.3m3.8m3.6m1.8m2.2m2.8m1.4m3.3m2.8m1.7m1.9m1.6m2.0m1.4m1.1m

R&D expense

4.5m

Operating expense total

1.6m4.1m4.4m7.0m7.9m7.4m4.6m6.0m6.9m7.1m7.8m7.2m6.7m6.4m4.9m6.2m5.7m5.1m

Depreciation and amortization

1.4k
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

5.5m6.7m25.6m20.5m17.4m13.7m

Accounts Receivable

2.1b

Inventories

218.4k699.9k803.5k1.8m

Current Assets

5.8m7.4m26.5m22.4m17.8m14.3m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(10.8m)(24.7m)(21.0m)(24.3m)(26.6m)(23.7m)

Depreciation and Amortization

1.6k37.9k53.5k77.5k55.9k50.7k

Inventories

106.6k(193.9k)162.1k(1.0m)

Accounts Payable

(518.1k)(793.9k)2.7m405.2k1.1m
USDY, 2019

EV/EBIT

-3.6 x

EV/CFO

-1.7 x

Financial Leverage

1.4 x
Show all financial metrics

Actinium Pharmaceuticals Online and Social Media Presence

Embed Graph

Actinium Pharmaceuticals News and Updates

Actinium Pharmaceuticals CD33 Program to Focus on Actimab-MDS Pivotal Trial Enabling Study for Targeted Conditioning and Novel Combination Trials with Actimab-A and Venetoclax

NEW YORK, Oct. 30, 2018 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) announced today that the next stage of development for its CD33 ARC (Antibody Radiation Conjugate) Ac-225-Lintuzumab program, after successful completion of the Actimab-A phase 2 trial in Acute...

Actinium Pharmaceuticals to Hold Webinar Showcasing Actimab-A Post Phase 2 Trial Plans and Actimab-MDS Regulatory Update

NEW YORK, Oct. 26, 2018 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) will host a conference call and webinar today at 11:00 AM ET to provide key updates on the advancement of its CD33 program that is based on the Antibody RadiationConjugate (ARC), Ac-225 –...

Actinium Pharmaceuticals Announces Webinar Showcasing Actimab-A Post Phase 2 Trial Plans and Actimab-MDS Regulatory Update

NEW YORK, Oct. 22, 2018 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) announced today that it will host a conference call and webinar to provide key updates on the advancement of its CD33 program on Friday, October 26, 2018 at 11:00 AM ET. Actinium's CD33 program...

Actinium Pharmaceuticals Blogs

Actinium Pharmaceuticals to Present at the Sachs 19th Annual Biotech in Europe Forum for Global Partnering & Investment

NEW YORK, Sept. 16, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that it will present at the Sachs 19th Annual Biotech in Europe Forum for Global Partnering & Investment. The forum is being held at the Congress Center Basel in Basel, Sw…

Actinium Pharmaceuticals to Present at the Rodman & Renshaw 21st Annual Global Investment Conference

NEW YORK, Sept. 5, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium"), today announced that it will present at the Rodman & Renshaw 21st Annual Global Investment Conference. The conference is being held at the Lotte New York Palace Hotel in New York City on…

Actinium Achieves Fifty Percent Enrollment in the Pivotal Phase 3 SIERRA Trial for Iomab-B

- Midpoint reached as 75th patient dosed in Phase 3 SIERRA trial - The SIERRA trial has yielded promising preliminary feasibility and safety data that were presented at ASH 2018, TCT 2019 and ASCO 2019 - Universal engraftment, strong donor chimerism and no 100-day non-relapse mortality observed i…

Actinium Poster Detailing Actinium-225 Labeled Daratumumab Selected in Top Poster Award Competition at 2019 Society of Nuclear Medicine and Molecular Imaging Annual Meeting

- Actinium poster selected from more than 1,110 posters presented at SNMMI awarded second place in oncology therapeutics track - Significantly higher cell killing ability and antitumor effect observed with Ac-225 labeled daratumumab compared to unlabeled daratumumab NEW YORK, June 26…

Actinium Presents New Data Demonstrating Effective Lymphodepletion with Lutetium-177 for CAR-T at the 2019 Society of Nuclear Medicine and Molecular Imaging Annual Meeting

- Actinium's - ACT or Adoptive Cell Therapy Program now capable of using multiple warheads, including iodine-131 and lutetium-177, to achieve lymphodepletion for CAR-T and adoptive cell therapies - CD45 targeted lymphodepletion selectively depletes lymphoid and myeloid immune cell populations while …

Actinium's Portfolio of Antibody Radiation-Conjugates to be Highlighted in Two Oral and Two Poster Presentations at the 2019 Society of Nuclear Medicine and Molecular Imaging Annual Meeting

- Pivotal Phase 3 Iomab-B program to be featured in oral presentations - Effective lymphodepletion with the radioisotope Lutetium-177 expands Actinium's Iomab-ACT program for CAR-T and adoptive cell therapies to multiple warheads NEW YORK, June 20, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, I…
Show more

Actinium Pharmaceuticals Frequently Asked Questions

  • When was Actinium Pharmaceuticals founded?

    Actinium Pharmaceuticals was founded in 2000.

  • Who are Actinium Pharmaceuticals key executives?

    Actinium Pharmaceuticals's key executives are Sandesh Seth, Mark Berger and Dale L. Ludwig.

  • How many employees does Actinium Pharmaceuticals have?

    Actinium Pharmaceuticals has 30 employees.

  • Who are Actinium Pharmaceuticals competitors?

    Competitors of Actinium Pharmaceuticals include Celcuity, Quark Pharmaceuticals and Horizon Discovery.

  • Where is Actinium Pharmaceuticals headquarters?

    Actinium Pharmaceuticals headquarters is located at 275 Madison Ave, New York.

  • Where are Actinium Pharmaceuticals offices?

    Actinium Pharmaceuticals has an office in New York.

  • How many offices does Actinium Pharmaceuticals have?

    Actinium Pharmaceuticals has 1 office.